Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression - PubMed (original) (raw)
Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression
William R Harrington et al. Mol Cell Endocrinol. 2003.
Abstract
Estrogens exert their regulatory transcriptional effects, which can be stimulatory or repressive, at diverse gene sites via two estrogen receptors, ERalpha and ERbeta. Since these two ERs have different tissue distributions, ligands that have the capacity to selectively activate or inhibit these two ERs would be useful in elucidating the biology of these two receptors and might assist in the development of estrogen pharmaceuticals with improved tissue selectivity. We have developed several ligands that showed ERalpha or ERbeta selectivity at promoter-gene sites containing consensus estrogen response elements (EREs): ERalpha-selective agonist (propyl-pyrazole-triol (PPT)), ERalpha-selective antagonist (methyl-piperidino-pyrazole (MPP)), ERbeta-potency selective agonist (diarylpropionitrile (DPN)) and ERbeta-selective antagonist/ERalpha-agonist (R,R-tetrahydrochrysene (R,R-THC)). In this study, we have examined the activity of these compounds at a range of gene sites where ER stimulates gene expression through non-consensus EREs (complement C3), or multiple half-EREs (NHE-RF/EBP50), or by tethering to DNA via other proteins (TGF beta3 and progesterone receptor A/AP-1), and at gene sites where ER represses gene transcription (interleukin-6). At all of these genes, PPT showed full stimulation through ERalpha while displaying no agonism through ERbeta. MPP antagonized estradiol actions on gene transactivation and transrepression through ERalpha, with little or no effect on transcription mediated through ERbeta. DPN displayed subtype-selective agonism, being ca. 30-fold more potent through ERbeta. R,R-THC was a complete antagonist through ERbeta and displayed agonism through ERalpha, the level of which was promoter dependent. Because these ligands maintain their agonist or antagonist character and ER subtype-selectivity at gene sites of diverse nature, where estradiol is either stimulatory or inhibitory, these compounds should prove useful in elucidating the biological functions of ERalpha and ERbeta.
Similar articles
- Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K, Katzenellenbogen JA. Katzenellenbogen BS, et al. J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):279-85. doi: 10.1016/s0960-0760(00)00104-7. J Steroid Biochem Mol Biol. 2000. PMID: 11162936 Review. - Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha.
Gougelet A, Mueller SO, Korach KS, Renoir JM. Gougelet A, et al. J Steroid Biochem Mol Biol. 2007 May;104(3-5):110-22. doi: 10.1016/j.jsbmb.2007.03.002. Epub 2007 Mar 12. J Steroid Biochem Mol Biol. 2007. PMID: 17478088 - Endogenous estrogen receptor beta is transcriptionally active in primary ovarian cells from estrogen receptor knockout mice.
Mueller SO, Katzenellenbogen JA, Korach KS. Mueller SO, et al. Steroids. 2004 Sep;69(10):681-6. doi: 10.1016/j.steroids.2004.06.004. Steroids. 2004. PMID: 15465114 - Estrogen receptors: selective ligands, partners, and distinctive pharmacology.
Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G, Martini PG, McInerney EM, Delage-Mourroux R, Weis K, Katzenellenbogen JA. Katzenellenbogen BS, et al. Recent Prog Horm Res. 2000;55:163-93; discussion 194-5. Recent Prog Horm Res. 2000. PMID: 11036937 Review.
Cited by
- Differential effects of estrogen receptor ligands on regulation of dihydrotestosterone-induced cell proliferation in endothelial and prostate cancer cells.
Weng C, Cai J, Wen J, Yuan H, Yang K, Imperato-McGinley J, Zhu YS. Weng C, et al. Int J Oncol. 2013 Jan;42(1):327-37. doi: 10.3892/ijo.2012.1689. Epub 2012 Nov 6. Int J Oncol. 2013. PMID: 23135751 Free PMC article. - Estrogen-receptor-mediated protection of cerebral endothelial cell viability and mitochondrial function after ischemic insult in vitro.
Guo J, Krause DN, Horne J, Weiss JH, Li X, Duckles SP. Guo J, et al. J Cereb Blood Flow Metab. 2010 Mar;30(3):545-54. doi: 10.1038/jcbfm.2009.226. Epub 2009 Oct 28. J Cereb Blood Flow Metab. 2010. PMID: 19861973 Free PMC article. - Vascular effects of estrogenic menopausal hormone therapy.
Reslan OM, Khalil RA. Reslan OM, et al. Rev Recent Clin Trials. 2012 Feb;7(1):47-70. doi: 10.2174/157488712799363253. Rev Recent Clin Trials. 2012. PMID: 21864249 Free PMC article. Review. - Effect of a putative ERalpha antagonist, MPP, on food intake in cycling and ovariectomized rats.
Santollo J, Eckel LA. Santollo J, et al. Physiol Behav. 2009 May 25;97(2):193-8. doi: 10.1016/j.physbeh.2009.02.021. Epub 2009 Feb 28. Physiol Behav. 2009. PMID: 19254732 Free PMC article. - Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels.
Smiley DA, Khalil RA. Smiley DA, et al. Curr Med Chem. 2009;16(15):1863-87. doi: 10.2174/092986709788186093. Curr Med Chem. 2009. PMID: 19442151 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous